TNDM TANDEM DIABETES CARE INC

Nasdaq tandemdiabetes.com


$ 14.66 $ -0.30 (-2.01 %)    

Thursday, 23-Oct-2025 15:59:59 EDT
QQQ $ 611.70 $ 5.09 (0.84 %)
DIA $ 467.20 $ 1.51 (0.32 %)
SPY $ 672.21 $ 3.96 (0.59 %)
TLT $ 91.38 $ -0.63 (-0.68 %)
GLD $ 378.90 $ 1.51 (0.4 %)
$ 14.66
$ 14.96
$ 14.46 x 70
$ 15.75 x 2
$ 14.63 - $ 15.07
$ 9.98 - $ 38.28
1,095,985
na
990.57M
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 02-26-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-22-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 04-30-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 07-30-2018 06-30-2018 10-Q
30 04-26-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 10-26-2017 09-30-2017 10-Q
33 07-27-2017 06-30-2017 10-Q
34 04-27-2017 03-31-2017 10-Q
35 03-08-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-28-2016 03-31-2016 10-Q
39 02-24-2016 12-31-2015 10-K
40 10-29-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-reinstates-hold-on-tandem-diabetes-care-announces-15-price-target

Stifel analyst Jonathan Block reinstates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and announces $15 price target.

 truist-securities-maintains-hold-on-tandem-diabetes-care-raises-price-target-to-16

Truist Securities analyst Richard Newitter maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price tar...

 citigroup-maintains-neutral-on-tandem-diabetes-care-raises-price-target-to-15

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target fro...

 canaccord-genuity-maintains-buy-on-tandem-diabetes-care-maintains-24-price-target

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ: TNDM) with a Buy and maintains $24 price ...

 tandem-diabetes-cares-tslim-x2-insulin-pump-with-control-iq-aid-technology-cleared-for-use-with-eli-lillys-lyumjev-ultra-rapid-acting-insulin-in-us

Tandem Diabetes Care, Inc.

 tandem-diabetes-study-finds-automated-insulin-delivery-benefits-adults-with-type-2-diabetes-regardless-of-c-peptide-levels-challenging-current-cms-coverage-criteria

This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and...

 jim-cramer-this-is-the-right-time-to-buy-this-energy-stock

Mad Money's Jim Cramer looks at Phillips 66 and Intuitive Surgical, as well as Tandem Diabetes Care and Cintas.

 oppenheimer-maintains-outperform-on-tandem-diabetes-care-lowers-price-target-to-22

Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price targ...

 citigroup-upgrades-tandem-diabetes-care-to-neutral-raises-price-target-to-1035

Citigroup analyst Joanne Wuensch upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Sell to Neutral and raises the price targe...

 barclays-maintains-overweight-on-tandem-diabetes-care-lowers-price-target-to-51

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from...

 canaccord-genuity-maintains-buy-on-tandem-diabetes-care-lowers-price-target-to-24

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price targ...

 on-aug-6-tandem-diabetes-care-announces-it-received-510k-fda-clearance-for-steadiset

-SEC Filing

 insulet-peer-tandem-diabetes-underwhelming-earnings-dull-outlook-drags-stock

Tandem Diabetes shares fall after a deeper loss, lower guidance, and a device recall tied to 700 adverse events and 59 injuries.

 ubs-maintains-neutral-on-tandem-diabetes-care-lowers-price-target-to-17

UBS analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $...

 rbc-capital-maintains-outperform-on-tandem-diabetes-care-lowers-price-target-to-25

RBC Capital analyst Shagun Singh maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target ...

 wells-fargo-maintains-equal-weight-on-tandem-diabetes-care-lowers-price-target-to-13

Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight and lowers the price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION